Compare Alcon AG (ALC) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs RLX Technology Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while RLX Technology Inc trades at $1.98 (market cap $2.32B). The key difference: Alcon AG is far larger — about 14.1× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.26%). Which is the better fit depends on your goals.
| ALC | RLX | |
|---|---|---|
Market Cap | $32.69B | $2.32B |
Sector | Health | Technology |
52-Week High | $92.22 | $2.73 |
52-Week Low | $62.02 | $1.79 |
Enterprise Value | $36.28B | $955.96M |
Dividend Yield | 0.54% | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
RLX stock trades at $1.96, up 1.55% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported strong 2025 results with $3.62B revenue and $922M net income, though recent quarters have missed EPS expectations. Positive news highlights international expansion and a cash-rich, debt-free balance sheet, with JPMorgan increasing its stake significantly in Q3 2025.
Outlook is cautiously optimistic given solid profitability and industry growth potential, but risks include regulatory scrutiny in the vaping sector and consistent earnings misses. The sole analyst coverage recommends Hold, reflecting balanced risk-reward amid high cash flows but uncertain near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
